Arvinas, Inc. (ARVN) shares surged 6.9% to close at $11.33, reversing a recent trend of decline amid heightened trading volume. This uptick follows positive investor sentiment surrounding the company’s early-stage study results for ARV-102, a treatment targeting LRRK2 for Parkinson’s disease. Notably, the study demonstrated a significant reduction of LRRK2 in cerebrospinal fluid, which has prompted Arvinas to further explore this drug in neurodegenerative diseases.
Despite this positive momentum, the company is projected to report a quarterly loss of $0.94 per share, a stark 182.5% decline year-over-year, with revenues expected to plummet 91% from the previous year. Additionally, the consensus EPS estimate has been revised 1.3% lower in the last month, which may dampen the stock’s near-term price appreciation potential.
Market professionals should monitor ARVN closely; while recent developments have sparked interest, the negative earnings trend could temper further gains.
Source: nasdaq.com